KdT Ventures

PathAI is transforming pathology through artificial intelligence, providing solutions for clinical development, translational research, and companion diagnostics.

Terray Therapeutics is focused on transforming small molecule drug discovery through a unique integration of high-quality experimental data and generative AI, enabling rapid identification and development of potent small molecules.

Dyno Therapeutics is a genetic technologies company applying artificial intelligence to solve the grand challenge of in vivo gene delivery, focusing on developing high-performance genetic technologies for transformative therapies.

Solugen is redefining chemical manufacturing by harnessing the power of biology and chemistry to create sustainable chemical solutions for various industries, including oil and gas, renewable fuels, and agriculture.

Azitra is a clinical-stage precision dermatology company that leverages its extensive knowledge of genetic engineering, proteomics, and the skin microbiome to create and develop novel products for the treatment of skin diseases.

Checkerspot harnesses biotechnology to produce high-performance fats and oils through precision fermentation of microalgae, offering sustainable alternatives to conventional sources.

Elegen specializes in cell-free clonal gene synthesis through its ENFINIA DNA technology, providing innovative solutions for genetic engineering and synthetic biology.

Abridge is a pioneering company leveraging generative AI to enhance clinical conversations, aiming to improve healthcare outcomes for clinicians, nurses, and revenue cycle teams. Their platform transforms healthcare interactions into actionable insights, fostering deeper understanding and efficiency in patient-provider communication.

STRM.BIO is developing a non-viral, cell-derived delivery platform for safe, targeted, and scalable in vivo delivery of genetic medicines, initially focused on rare hematological diseases such as Fanconi anemia and in vivo CAR-T therapies.

Hi Fidelity Genetics offers premium non-GMO corn and soybean seeds, focusing on providing farmers with cost-effective solutions to improve their yields.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.

Founded in 2002, +ND invests in disruptive technologies spanning life, physical, and data sciences, prioritizing opportunities driven by scientific convergence.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.